1. GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi
No.2/2/2003-F.Sec. Dated: 25-07-2007
To,
The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi
Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 02-6-2007 TO BE PUBLISHED ON 26-7-2007 IN
THE GAZETTE OF PAKISTAN PART-V.
A manuscript copy of the weekly notification regarding application filed
application accepted and scaling fee due etc., is forwarded herewith to be published in the
next issue of the Gazette of Pakistan Part-V without fail.
(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Ph: 9215488
ENCL:

2. NEW APPLICATIONS FOR THE PATENTS
The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance
2000.
28-05-2007
607/2007 F. L. Smith A/S.
Denmark
(Priority 08-9-06 Denmark)
“Temperature stable cast-iron alloy and its
use”
608/2007 Elan Pharmaceutical, Inc.
USA
(Priority 02-6-06 US)
“ Fused tricyclic sulfonamide inhibitors of
gamma secretase”
609/2007 F. Hoffmann-La Roche AG,
Switzerland
(Priority 12-2-01 US)
Divisional
“ Process for the preparation of 6-substituted
pyrido-pyrimidines”
610/2007 Novartis AG,
Switzerland
(Priority 31-5-06 US)
“ Aminothiazoles and their uses”
611/2007 Glaxo Group Limited.
United Kingdom
(Priority 30-5-06 GB)
“ Compounds”
29-5-2007
612/2007 SmithKline Beecham Corporation,
USA
(Priority 02-6-06 US)
“ Benzimidazole thiophene compounds”
613/2007 AstraZeneca AB,
Sweden
(Priority 20-2-04 GB)
Divisional
“ A pharmaceutically acceptable salt of 1,5-
diarylpyrazole-3-carboxamides as CB1
modulators for the treatment of obesity”
614/2007 Janssen Pharmaceutica N. V.
Belgium
(Priority 02-6-06 EPO)
“ Novel n-aryland n-heteroaryl substituted
pyridinone derivates for use in mch-1
mediated diseases”
615/2007 Janssen Pharmaceutica N. V.
Belgium
(Priority 01-6-06 USA)
“Treatment of hot flashesusing muscarini
creceptor antagosnists”
616/2007 Janssen Pharmaceutica N. V.
Belgium
(Priority 30-6-06 USA)
“ Substituted pyridyl amide compounds as
modulators of the histamine H3 receptor”
617/2007 Ortloff Engineets, Ltd. “ Liquefied natural Gas processing”

3. USA
(Priority 02-6-06 US)
618/2007 Janssen Pharmaceutica N. V.
Belgium
(Priority 01-6-06 USA)
“Treatment of hot flashes using muscarinic
receptor antagonists”
619/2007 Glaxo Group Limited,
United Kingdom
(Priority 31-5-06 EP)
“ Novel heterocyclic compounds”
620/2007 Sanofi-Aventis Deutschland GmbH
Germany
(Priority 01-6-06 Germany)
“ Spirocyclic nitriles as protease inhibitors”
31-5-2007
621/2007 GlaxoSmithKline Biologicals, s.a.
Belgium
(Priority 02-6-06 GB)
“ Method”
622/2007 Bristol-Myers Squibb Company,
USA
(Priority 06-2-04 US)
Divisional
“Process for preparing 2-aminothiazole-5-
aromatic carboxamide as kinase inhibitor”
623/2007 1.Dr. Tariq Masud and
2. Ahmad Bilal,
University of Arid Agriculture
Rawalpindi Department of food
Technology
“ Regulation of glucose and lipid profile in
type 2 diabetic patients by using nigella
sativa seed powder”
624/2007 Graf + Cie AG,
Switzerland
(Priority 23-6-06 Germany)
“ Combing means for a comb of a combing
machine”
625/2007 Otsuka Pharmaceutical Co., Ltd.
Japan
(Priority 19-6-06 US)
“ Method of using a thiazole derivative”
626/2007 Sanofi-Aventis
France
(Priority 07-6-06 France)
“ Use of a cannabinoid CBI receptor
antagonist for the preparation of
medicaments that can be use for the
prevention and treatment of benign prostate
hypertrophy”
01-6-2007
627/2007 Wyeth,
USA
(Priority 02-6-06 USA)
“ Methods for preparing glutamic acid
derivatives and intermediates thereof”
628/2007 Wyeth,
USA
“ Benzoxazole and benzothiazole derivatives
as 5-hydroxyptamine-6 ligands”

4. (Priority 01-6-06 USA)
629/2007 H. Lundbeck A/S
Denmark
(Priority 01-6-06 DK)
“ Use of sertindole for the preventive
treatment of suicidal behaviour”
630/2007 Sanofi-Aventis
France
(Priority 13-6-06 France)
“ Dual molecules containing a peroxide
derivative, synthesis thereof and therapeutic
applications thereof”
631/2007 1.Li Shu, Managing Director
2. Plum Qingqi Motors, Ltd.
China
“ For forced air cooling system, air gas mixer
& box differential & reverse system”
02-6-2007
632/2007 Glaxo Group Limited,
United Kingdom
(Priority 14-10-03 USA)
Divisional
“ 8-azoniabicyclo [3,2,1] octane compound
and a pharmaceutical composition
comprising thereof for the treatment of
muscarinic acetylcholine receptor mediated
diseases”
633/2007 Glaxo Group Limited,
United Kingdom
(Priority 14-10-03 USA)
Divisional
“ 8-azoniabicyclo [3,2,1] octane compound
and a pharmaceutical composition
comprising thereof for the treatment of
muscarinic acetylcholine receptor mediated
diseases”
634/2007 Nawab Ikramullah Khan
Islamabad, Pakistan
“ 100% hazard free screened switch using
magnetic flux and glass”
APPLICATION ACCEPTED
Notice is hereby given that the person interested in opposing the grant of Patents to any
of the applications referred to below at any time within four months from the date of this
Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents
Rules 18(1) of 2003.
The six figures number shown in the right hand side are those given to applications on
acceptance of the complete specification under which the specification will be printed
and subsequent proceeding taken.
The figures shown within square brackets after the title of inventions indicate their
classification index at acceptance.
Typed copies of the specification which are to open to public inspection can be supplied
by the Patent Office on payment of the prescribed charges which may be as certained on
application to the office.

5. 515/99 Pfizer Products Inc.
USA
“Pyrrolo [2,3-d] pyrimidine compound”
(Class: Co7D, 239)
139276
A compound of the formula
wherein R1, R2 and R3 are as defined above, which
are inhibitors of the enzyme protein tyrosine kinases
such as Janus Kinase 3 and as such are useful therapy
as immunosuppressive agents for organ transplants,
lupus, multiple sclerosis, rheumatoid arthritis,
psoriasis, type I diabetes and complications from
diabetes, cancer, asthma, atopic dermatitis ,
autoimmune thyroid disorders, ulcerative colitis,
Crohn’s disease, Alzheimer’s disease, Leukemia and
other autoimmune diseases.

6. 467/2000 Pfizer Products Inc.
USA
“A suspension comprising ziprasidone hydrochloride”
(Class: CO7D 275/06, CO7D 241/04, CO7D 209/02)
139277
Compositions comprising ziprasidone free base or a
difficult to wet pharmaceutically acceptable
ziprasidone acid addition salt, a polysorbate, and
colloidal silicon dioxide form good aqueous
suspensions having a useful shelf life and are easily
re-suspended if setting occurs.
49/2003 Aventis Pharma S.A.,
France
“ Azabicyclo [3.2.1] octane-4-propanoic acid as
inhibitor of beta-lactamase”
(A61K 31/46)
139278
The invention relates to the use of the compounds of
formula (I)
For the preparation of a medicament intended to
inhibit the production of β-lactamases by pathogenic
bacteria.

7. SEALING FEES DUE
Notice is hereby given that the Patent may now be sealed on the application referred to
below if it is desired that Patent should be sealed a request on the prescribed Form-10
accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and
Designs, The Patent Office, Karachi.
139274 Pfizer Products Inc.
USA
892/98
139275 Pfizer Products Inc.
USA
420/2007
(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Tel: 9215488